The Role of X-Linked Inhibitor of Apoptosis Protein in Chemoresistant Ovarian Cancer

The Ovary: Second Edition

Volumn , Issue , 2004, Pages 613-624

  Fraser, Michael ^a   Tsang, Benjamin K ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942772432     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012444562-8/50038-0     Document Type: Chapter

References (99)

1. Rubin S.C., Sutton G.P. Ovarian Cancer 2001, Lippincott Williams & Wilkins, New York. 2nd ed.
2. http://www.cancer.org/downloads/STT/F&F2001/pdf.
3. Legros M., Dauplat J., Fleury J., Cure H., Suzanne F., Chassagne J., Bay J.O., Sol C., Canis M., Condat P., Choufi B., Tavernier F., Glenat C., Chollet P., Plagne R. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J. Clin. Oncol. 1997, 15:1302-1308.
4. Sasaki H., Sheng Y., Kotsuji F., Tsang B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000, 60:5659-5666.
5. Gately D.P., Howell S.B. Cellular accumulation of the anticancer agent cisplatin: A review. Br. J. Cancer. 1993, 67:1171-1176.
6. Bose R.N. Biomolecular targets for platinum antitumor drug. Mini. Rev. Med. Chem. 2002, 2:103-111.
7. Riordan J.R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985, 316:817-819.
8. Cole S.P., Deeley R.G. Multidrug resistance-associated protein: Sequence correction. Science 1993, 260:879.
9. Scheffer G.L., Wijngaard P.L., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J., Clevers H.C., Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1995, 1:578-582.
10. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 1987, 84:3004-3008.
11. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54:5902-5910.
12. Taniguchi K., Wada M., Kohno K., Nakamura T., Kawabe T., Kawakami M., Kagotani K., Okumura K., Akiyama S., Kuwano M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996, 56:4124-4129.
13. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57:3537-3547.
14. Izquierdo M.A., Scheffer G.L., Flens M.J., Giaccone G., Broxterman H.J., Meijer C.J., van der Valk P., Scheper R.J. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am. J. Pathol. 1996, 148:877-887.
15. Izquierdo M.A., van der Zee A.G., Vermorken J.B., van der Valk P., Belien J.A., Giaccone G., Scheffer G.L., Flens M.J., Pinedo H.M., Kenemans P., et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst. 1995, 87:1230-1237.
16. Komatsu M., Sumizawa T., Mutoh M., Chen Z.S., Terada K., Furukawa T., Yang X.L., Gao H., Miura N., Sugiyama T., Akiyama S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 2000, 60:1312-1316.
17. Nakayama K., Kanzaki A., Ogawa K., Miyazaki K., Neamati N., Takebayashi Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Intl. J. Cancer. 2002, 101:488-495.
18. Cheng J.Q., Jiang X., Fraser M., Li M., Dan H.C., Sun M., Tsang B.K. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: Possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Update 2002, 5:131-146.
19. Li J., Sasaki H., Sheng Y.L., Schneiderman D., Xiao C.W., Kotsuji F., Tsang B.K. Apoptosis and chemoresistance in human ovarian cancer: Is Xiap a determinant?. Biol. Signals Recept. 2000, 9:122-130.
20. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 1998, 24:331-344.
21. Zamble D.B., Lippard S.J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci. 1995, 20:435-439.
22. Eastman A., Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 1988, 27:4730-4734.
23. Parker R.J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 1991, 87:772-777.
24. Sheibani N., Jennerwein M.M., Eastman A. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): Host cell reactivation of damaged plasmid DNA. Biochemistry 1989, 28:3120-3124.
25. Chu G., Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc. Natl. Acad. Sci. USA 1990, 87:3324-3328.
26. Zhen W., Link C.J., O'Connor P.M., Reed E., Parker R., Howell S.B., Bohr V.A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell. Biol. 1992, 12:3689-3698.
27. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst. 1992, 84:1512-1517.
28. Sung P., Bailly V., Weber C., Thompson L.H., Prakash L., Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993, 365:852-855.
29. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001, 61:8654-8658.
30. Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G., Farahani R., McLean M., Ikeda J.E., MacKenzie A., Korneluk R.G. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996, 379:349-353.
31. Rothe M., Pan M.G., Henzel W.J., Ayres T.M., Goeddel D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995, 83:1243-1252.
32. Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
33. Suzuki Y., Nakabayashi Y., Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. USA 2001, 98:8662-8667.
34. MacFarlane M., Merrison W., Bratton S.B., Cohen G.M. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J. Biol. Chem. 2002, 277:36611-36616.
35. Li J., Feng Q., Kim J.M., Schneiderman D., Liston P., Li M., Vanderhyden B., Faught W., Fung M.F., Senterman M., Korneluk R.G., Tsang B.K. Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins. Endocrinology 2001, 142:370-380.
36. Asselin E., Mills G.B., Tsang B.K. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001, 61:1862-1868.
37. Birkey Reffey S., Wurthner J.U., Parks W.T., Roberts A.B., Duckett C.S. X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. J. Biol. Chem. 2001, 276:26542-26549.
38. Yamaguchi K., Nagai S., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K., Ueno N., Nishida E., Shibuya H., Matsumoto K. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. Embo. J. 1999, 18:179-187.
39. Yamaguchi A. Regulation of differentiation pathway of skeletal mesenchymal cells in cell lines by transform-ing growth factor-beta superfamily. Semin. Cell. Biol. 1995, 6:165-173.
40. Sanna M.G., Duckett C.S., Richter B.W., Thompson C.B., Ulevitch R.J. Selective activation of JNK1 is necessary for the anti-apoptotic activity of hILP. Proc. Natl. Acad. Sci. USA 1998, 95:6015-6020.
41. Sanna M.G., da Silva Correia J., Ducrey O., Lee J., Nomoto K., Schrantz N., Deveraux Q.L., Ulevitch R.J. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol. Cell. Biol. 2002, 22:1754-1766.
42. Sanna M.G., da Silva Correia J., Luo Y., Chuang B., Paulson L.M., Nguyen B., Deveraux Q.L., Ulevitch R.J. ILPIP, a novel anti-apoptotic protein that enhances XIAP-mediated activation of JNK1 and protection against apoptosis. J. Biol. Chem. 2002, 277:30454-30462.
43. Berchuck A., Olt G.J., Everitt L., Soisson A.P., Bast R.C., Boyer C.M. The role of peptide growth factors in epithelial ovarian cancer. Obstet. Gynecol. 1990, 75:255-262.
44. Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P., Arrick B.A., Clarke-Pearson D.L., Bast R.C. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am. J. Obstet. Gynecol. 1992, 166:676-684.
45. Marth C., Lang T., Koza A., Mayer I., Daxenbichler G. Transforming growth factor-beta and ovarian carcinoma cells: Regulation of proliferation and surface antigen expression. Cancer Lett. 1990, 51:221-225.
46. Bartlett J.M., Rabiasz G.J., Scott W.N., Langdon S.P., Smyth J.F., Miller W.R. Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells. Br. J. Cancer. 1992, 65:655-660.
47. Jozan S., Guerrin M., Mazars P., Dutaur M., Monsarrat B., Cheutin F., Bugat R., Martel P., Valette A. Transforming growth factor beta 1 (TGF-beta 1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors. Intl. J. Cancer. 1992, 52:766-770.
48. Rabiasz G.J., Langdon S.P., Bartlett J.M., Crew A.J., Miller E.P., Scott W.N., Smyth J.F., Miller W.R. Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells. Br. J. Cancer. 1992, 66:254-259.
49. Zhou L., Leung B.S. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors alpha and beta 1. Biochim. Biophys. Acta. 1992, 1180:130-136.
50. Leevers S.J., Vanhaesebroeck B., Waterfield M.D. Signalling through phosphoinositide 3-kinases: The lipids take centre stage. Curr. Opin. Cell. Biol. 1999, 11:219-225.
51. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 1992, 89:9267-9271.
52. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 1987, 84:5034-5037.
53. Rane M.J., Coxon P.Y., Powell D.W., Webster R., Klein J.B., Pierce W., Ping P., McLeish K.R. p38 Kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils. J. Biol. Chem. 2001, 276:3517-3523.
54. Delcommenne M., Tan C., Gray V., Rue L., Woodgett J., Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. USA 1998, 95:11211-11216.
55. Balendran A., Casamayor A., Deak M., Paterson A., Gaffney P., Currie R., Downes C.P., Alessi D.R. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr. Biol. 1999, 9:393-404.
56. Aman M.J., Lamkin T.D., Okada H., Kurosaki T., Ravichandran K.S. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 1998, 273:33922-33928.
57. Liu Q., Sasaki T., Kozieradzki I., Wakeham A., Itie A., Dumont D.J., Penninger J.M. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 1999, 13:786-791.
58. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
59. Li J., Simpson L., Takahashi M., Miliaresis C., Myers M.P., Tonks N., Parsons R. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 1998, 58:5667-5672.
60. Saito M., Okamoto A., Kohno T., Takakura S., Shinozaki H., Isonishi S., Yasuhara T., Yoshimura T., Ohtake Y., Ochiai K., Yokota J., Tanaka T. Allelic imbalance and multations of the PTEN gene in ovarian cancer. Intl. J. Cancer. 2000, 85:160-165.
61. Schondorf T., Dostal A., Grabmann J., Gohring U.J. Single mutations of the PTEN gene in recurrent ovarian carcinomas. J. Soc. Gynecol. Investig. 2000, 7:313-316.
62. Yokomizo A., Tindall D.J., Hartmann L., Jenkins R.B., Smith D.I., Liu W. Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. Intl. J. Oncol. 1998, 13:101-105.
63. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999, 21:99-102.
64. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., Coppola D., Nicosia S.V., Cheng J.Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000, 19:2324-2330.
65. Phillips W.A., St Clair F., Munday A.D., Thomas R.J., Mitchell C.A. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 1998, 83:41-47.
66. Moore S.M., Rintoul R.C., Walker T.R., Chilvers E.R., Haslett C., Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res. 1998, 58:5239-5247.
67. Sun M., Paciga J.E., Feldman R.I., Yuan Z., Coppola D., Lu Y.Y., Shelley S.A., Nicosia S.V., Cheng J.Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001, 61:5985-5991.
68. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw E.B., Kaestner K.H., Bartolomei M.S., Shulman G.I., Birnbaum M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001, 292:1728-1731.
69. Cho H., Thorvaldsen J.L., Chu Q., Feng F., Birnbaum M.J. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 2001, 276:38349-38352.
70. Chen W.S., Xu P.Z., Gottlob K., Chen M.L., Sokol K., Shiyanova T., Roninson I., Weng W., Suzuki R., Tobe K., Kadowaki T., Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001, 15:2203-2208.
71. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
72. del Peso L., Gonzalez-Garcia M., Page C., Herrera R., Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689.
73. Jiang K., Coppola D., Crespo N.C., Nicosia S.V., Hamilton A.D., Sebti S.M., Cheng J.Q. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol. 2000, 20:139-148.
74. Tang Y., Zhou H., Chen A., Pittman R.N., Field J. The Akt proto-oncogene links Ras to Pak and cell survival signals. J. Biol. Chem. 2000, 275:9106-9109.
75. Biggs W.H., Meisenhelder J., Hunter T., Cavenee W.K., Arden K.C. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA 1999, 96:7421-7426.
76. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
77. Brunet A., Park J., Tran H., Hu L.S., Hemmings B.A., Greenberg M.E. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 2001, 21:952-965.
78. Kops G.J., de Ruiter N.D., De Vries-Smits A.M., Powell D.R., Bos J.L., Burgering B.M. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 1999, 398:630-634.
79. Tang E.D., Nunez G., Barr F.G., Guan K.L. Negative regulation of the forkhead transcription factor FKHR by Akt. J. Biol. Chem. 1999, 274:16741-16746.
80. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: A play in three Akts. Genes Dev. 1999, 13:2905-2927.
81. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 2001, 98:11598-11603.
82. Fraser M., Leung B.M., Yan X., Dan H.C., Cheng J.Q., Tsang B.K. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 2003, In Press.
83. Rossig L., Jadidi A.S., Urbich C., Badorff C., Zeiher A.M., Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol. Cell. Biol. 2001, 21:5644-5657.
84. Cheng J.Q., Altomare D.A., Klein M.A., Lee W.C., Kruh G.D., Lissy N.A., Testa J.R. Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 1997, 14:2793-2801.
85. Mende I., Malstrom S., Tsichlis P.N., Vogt P.K., Aoki M. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 2001, 20:4419-4423.
86. Zhou B.P., Hu M.C., Miller S.A., Yu Z., Xia W., Lin S.Y., Hung M.C. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem. 2000, 275:8027-8031.
87. Page C., Lin H.J., Jin Y., Castle V.P., Nunez G., Huang M., Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 2000, 20:407-416.
88. Hu L., Hofmann J., Lu Y., Mills G.B., Jaffe R.B. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002, 62:1087-1092.
89. Liu M.C., Gelmann E.P. P53 gene mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 2002, 29:246-257.
90. Erhardt P., Tomaselli K.J., Cooper G.M. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J. Biol. Chem. 1997, 272:15049-15052.
91. Chen L., Marechal V., Moreau J., Levine A.J., Chen J. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J. Biol. Chem. 1997, 272:22966-22973.
92. Persons D.L., Yazlovitskaya E.M., Pelling J.C. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J. Biol. Chem. 2000, 275:35778-35785.
93. Unger T., Sionov R.V., Moallem E., Yee C.L., Howley P.M., Oren M., Haupt Y. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 1999, 18:3205-3212.
94. Shono T., Tofilon P.J., Schaefer T.S., Parikh D., Liu T.J., Lang F.F. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res. 2002, 62:1069-1076.
95. Yang A., McKeon F. P63 and P73: P53 mimics, menaces and more. Nat. Rev. Mol. Cell. Biol. 2000, 1:199-207.
96. Michael D., Oren M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 2002, 12:53-59.
97. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416:560-564.
98. Di Como C.J., Urist M.J., Babayan I., Drobnjak M., Hedvat C.V., Teruya-Feldstein J., Pohar K., Hoos A., Cordon-Cardo C. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002, 8:494-501.
99. Vikhanskaya F., D'Incalci M., Broggini M. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Res. 2000, 28:513-519.